Rosetta Inpharmatics Establishes New Business Unit Rosetta Biosoftware | GenomeWeb

NEW YORK, Sept. 20 – Merck's wholly owned subsidiary Rosetta Inpharmatics said Thursday it had established a new business unit, Rosetta Biosoftware, to develop and sell new bioinformatics software for life science research.

The new business unit, which will be based in Kirkland, Wash., will continue to develop new versions of Rosetta’s flagship product, the Rosetta Resolver Gene Expression Data Analysis System.

Agilent Technologies will remain the exclusive distributor of Rosetta software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.